Coverart for item
The Resource Advances in targeted cancer therapy, edited by Paul L. Herrling, Alex Matter, Richard M. Schultz, (electronic book)

Advances in targeted cancer therapy, edited by Paul L. Herrling, Alex Matter, Richard M. Schultz, (electronic book)

Label
Advances in targeted cancer therapy
Title
Advances in targeted cancer therapy
Statement of responsibility
edited by Paul L. Herrling, Alex Matter, Richard M. Schultz
Contributor
Subject
Language
eng
Summary
This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed
Member of
Cataloging source
GW5XE
Dewey number
616.99/4061
Illustrations
illustrations
Index
index present
LC call number
RC271.C5
LC item number
A28 2005eb
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorName
Schultz, Richard M
http://library.link/vocab/subjectName
  • Cancer
  • Drug targeting
  • Neoplasms
  • Antineoplastic Agents
  • Drug Delivery Systems
Label
Advances in targeted cancer therapy, edited by Paul L. Herrling, Alex Matter, Richard M. Schultz, (electronic book)
Instantiates
Publication
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
Dawn of a new era in molecular cancer therapeutics -- Obstacles and opportunities in the clinical development of targeted therapeutics -- Tumor models for preclinical development of targeted agents -- Angiogenesis inhibitors: what is the clinical future? -- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy -- Cell survival signaling during apoptosis: implications in drug resistance and anti-cancer therapeutic development -- Targeted histone deacetylase inhibition for cancer prevention and therapy -- Inhibitors of cyclin-dependent kinase modulators for cancer therapy -- Targeting cyclooxygenase-2 for cancer prevention and treatment -- Antisense approaches in drug discovery and development -- Preclinical development of Alimta (Pemetrexed LY231514), a multitargeted antifolate
Control code
SPR262681496
Dimensions
unknown
Extent
1 online resource (vii, 303 pages)
Form of item
online
Isbn
9783764371746
Lccn
2006531135
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other physical details
illustrations.
Specific material designation
remote
Label
Advances in targeted cancer therapy, edited by Paul L. Herrling, Alex Matter, Richard M. Schultz, (electronic book)
Publication
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
Dawn of a new era in molecular cancer therapeutics -- Obstacles and opportunities in the clinical development of targeted therapeutics -- Tumor models for preclinical development of targeted agents -- Angiogenesis inhibitors: what is the clinical future? -- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy -- Cell survival signaling during apoptosis: implications in drug resistance and anti-cancer therapeutic development -- Targeted histone deacetylase inhibition for cancer prevention and therapy -- Inhibitors of cyclin-dependent kinase modulators for cancer therapy -- Targeting cyclooxygenase-2 for cancer prevention and treatment -- Antisense approaches in drug discovery and development -- Preclinical development of Alimta (Pemetrexed LY231514), a multitargeted antifolate
Control code
SPR262681496
Dimensions
unknown
Extent
1 online resource (vii, 303 pages)
Form of item
online
Isbn
9783764371746
Lccn
2006531135
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other physical details
illustrations.
Specific material designation
remote

Library Locations

Processing Feedback ...